Why DBV Technologies Is a High-Risk, High-Reward Long — My $42 Fair Value Still Stands
DBV is a clinical-stage immunotherapy company whose VIASKIN Peanut patch just had a BLA filed with the FDA and is seeking priority review. The stock has plunged ~55% since April, but the core commercial opportunity — if the product is approved and adopted — supports a $42 fair value per ADS. This trade idea is directional: a long position entered n…